GO
Loading...

Roche Holding AG

More

  • Aug 27- Roche Holding AG's planned $8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company's development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck.

  • Aug 26- Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck& Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S. drugmakers said the combination study will begin in 2015 and be conducted by Pfizer.

  • Earnings season: Here's what we’ve learned Tuesday, 26 Aug 2014 | 7:50 AM ET

    What have we learnt from the recent reporting flurry? Societe Generale has put together a list of conclusions to be drawn from this earnings season.

  • After crossing 2,000, record-high close for S&P 500 Monday, 25 Aug 2014 | 4:35 PM ET
    Trader on the floor of the New York Stock Exchange.

    Stocks rose on Monday as investors welcomed M&A and looked to the European Central Bank for further monetary easing moves.

  • NEW YORK, Aug 25- The S&P 500 was unable to hold the 2,000 mark after moving above the milestone level for the first time on Monday, but still managed to close at a record high, buoyed by financials and biotechnology stocks.

  • NEW YORK, Aug 25- The S&P 500 briefly hurdled above 2,000 for the first time on Monday, with financials and biotechnology stocks lifting the benchmark index to a record as investors make equities their asset of choice.

  • Europe closes higher on Draghi, Wall Street gains Monday, 25 Aug 2014 | 12:47 PM ET

    European shares closed higher on Monday following a key speech by Mario Draghi, the president of the European Central Bank.

  • There's still hunger for 'blockbuster' biotech deals Monday, 25 Aug 2014 | 10:58 AM ET
    Severin Schwan, chief executive officer Roche Holding.

    Roche's deal for InterMune is one of the few this year that returns to the traditional model of big pharma buying smaller biotech.

  • Biotechs rallied after Roche Holding AG agreed to buy InterMune Inc for $8.3 billion in cash, the latest vote of confidence in a sector that many, including Federal Reserve Chair Janet Yellen, are worried is overvalued. InterMune jumped 36 percent to $73.00, with the Nasdaq Biotech index up 2.4 percent.

  • *Roche to buy InterMune for $8.3 billion. *U.S. investors took cues from Europe, where an index of major shares rose 0.7 percent after European Central Bank President Mario Draghi said Friday the ECB was prepared to respond with available tools if inflation dropped further.

  • US stock futures gain on M&A, hope for ECB stimulus Monday, 25 Aug 2014 | 8:36 AM ET

    U.S. stock-index futures rose on Monday, following European shares higher, as traders digested comments by the Fed's Yellen and the ECB's Draghi.

  • *Roche to buy InterMune for $8.3 billion. *U.S. investors took cues from Europe, where an index of major shares rose 0.7 percent after European Central Bank President Mario Draghi said Friday the ECB was prepared to respond with available tools if inflation dropped further.

  • Roche is buying biotech company InterMune for $74 per share, reports CNBC's Meg Tirrell.

  • LOS ANGELES, Aug 25- U.S. regulators are likely to approve Merck& Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

  • Surani Fernando, EMEA deputy editor at Biopharm Insight, says she was "surprised" at the value of Roche's $8.3 billion purchase of Intermune.

  • *Euro STOXX 50 index rises 1.1 percent. LONDON, Aug 25- European shares rose in morning trading on Monday, with market sentiment improving after comments by European Central Bank President Mario Draghi raised expectations of further policy easing.

  • *Deal boosts Roche presence in respiratory medicine. LONDON/ ZURICH, Aug 24- Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector.

  • Roche to purchase InterMune in $8.3 billion deal Sunday, 24 Aug 2014 | 12:27 PM ET

    Biotech firm Roche announced plans Sunday to buy InterMune for $8.3 billion on a fully diluted basis in an all-cash transaction.

  • Roche to buy U.S. biotech firm InterMune for $8.3 bln Sunday, 24 Aug 2014 | 12:25 PM ET

    LONDON, Aug 24- Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc for $8.3 billion in cash, marking the latest multibillion-dollar deal in a consolidating pharmaceutical sector, Roche said on Sunday.

  • SAN FRANCISCO, Aug 22- Genentech Inc is on the hunt for partnerships and investment opportunities in medical-technology startups, Chief Executive Officer Ian Clark told Reuters, underscoring the industry's growing interest in digital healthcare.